Disease control and treatment pathways of asthma patients after initiating ICS/LABA

Pneumologie 2019; 73(S 01)
DOI: 10.1055/s-0039-1678050

Posterbegehung (P05) – Sektion Klinische Pneumologie

Asthma 2019

Georg Thieme Verlag KG Stuttgart · New York

R Buhl

¹Universitätsmedizin Mainz, Med. Klinik III, Schwerpunkt Pneumologie

,

L Heaney

²Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queenʼs University Belfast

,

E Loefroth

³Novartis Sverige Ab, Täby (Sweden)

,

M Larbig

⁴Novartis Pharma AG, Basel (Switzerland)

,

K Konstantinos

⁴Novartis Pharma AG, Basel (Switzerland)

,

V Corti

⁴Novartis Pharma AG, Basel (Switzerland)

,

H Cao

⁵Novartis Pharmaceuticals Corporation, East Hanover (USA)